The overall goal of this award was to complete several needed activities for the development of an immune cell-based therapy for patients with the deadly brain tumor, glioblastoma multiforme (GBM). To make this therapy, T cells from the patient’s own body are isolated and genetically modified to recognize the tumor cells and kill them. The activities that we completed under this award include clinical grade manufacture of the viral vector used to genetically modify the T cells, demonstration that the T cell product can be made reproducibly using that viral vector, and carrying out safety and efficacy studies using the manufactured product. In addition, we completed a pre-IND meeting to discuss our data and next steps with the FDA, and we have now submitted the minutes from that meeting to CIRM, thus completing the activities of this award.